Ian Hayes
Keine laufenden Positionen mehr
Profil
Ian Hayes is the founder of EiRx Therapeutics Plc.
Prior to that, he worked as a Director of Business Development at Crescent Diagnostics Ltd., Radisens Diagnostics Ltd., and as a Principal at OSI Pharmaceuticals, Inc. He holds a doctorate and an undergraduate degree from the University of East Anglia.
Ehemalige bekannte Positionen von Ian Hayes
Unternehmen | Position | Ende |
---|---|---|
OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Crescent Diagnostics Ltd.
Crescent Diagnostics Ltd. Medical/Nursing ServicesHealth Services Crescent Diagnostics Ltd. operates as a medical diagnostics company. The firm offers bone quality test, an osteoporosis screening tool that enables clinicians to identify those who are at high risk of suffering a hip fracture. The company was founded by Mark Towler and Ernest Poku in 2004 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Radisens Diagnostics Ltd.
Radisens Diagnostics Ltd. Medical SpecialtiesHealth Technology Radisens Diagnostics Ltd. operates as a medical diagnostics company that develops a near-patient device to instantly test for high-burden chronic disease. It specializes in the decentralization of routine blood testing from central reference laboratories into physician offices, outpatient clinics, hospital bedsides and other point-of-care settings. With a finger-prick of blood, this multi-mode diagnostic device will return laboratory-grade results within minutes during a patient’s physician visit. The firm offers patients test results for any condition, anywhere, instantly. The company was founded in 2009 by Jeremiah O'Brien and is headquartered in Ballincollig, Ireland. | Corporate Officer/Principal | - |
EiRx Therapeutics Plc
EiRx Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services The Group's principal activity is discovering and developing novel therapeutics for the treatment of cancer. It focuses on the study of cancer cell survival and growth, with a research base encompassing apoptosis biology, cancer biomarkers and the metabolic basis of drug resistance in tumours. The Group creates intellectual property that seeks to exploit through in-house product development and licensing. | Gründer | - |
Ausbildung von Ian Hayes
University of East Anglia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
EiRx Therapeutics Plc
EiRx Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services The Group's principal activity is discovering and developing novel therapeutics for the treatment of cancer. It focuses on the study of cancer cell survival and growth, with a research base encompassing apoptosis biology, cancer biomarkers and the metabolic basis of drug resistance in tumours. The Group creates intellectual property that seeks to exploit through in-house product development and licensing. | Commercial Services |
Crescent Diagnostics Ltd.
Crescent Diagnostics Ltd. Medical/Nursing ServicesHealth Services Crescent Diagnostics Ltd. operates as a medical diagnostics company. The firm offers bone quality test, an osteoporosis screening tool that enables clinicians to identify those who are at high risk of suffering a hip fracture. The company was founded by Mark Towler and Ernest Poku in 2004 and is headquartered in London, the United Kingdom. | Health Services |
Radisens Diagnostics Ltd.
Radisens Diagnostics Ltd. Medical SpecialtiesHealth Technology Radisens Diagnostics Ltd. operates as a medical diagnostics company that develops a near-patient device to instantly test for high-burden chronic disease. It specializes in the decentralization of routine blood testing from central reference laboratories into physician offices, outpatient clinics, hospital bedsides and other point-of-care settings. With a finger-prick of blood, this multi-mode diagnostic device will return laboratory-grade results within minutes during a patient’s physician visit. The firm offers patients test results for any condition, anywhere, instantly. The company was founded in 2009 by Jeremiah O'Brien and is headquartered in Ballincollig, Ireland. | Health Technology |